ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.
Zhou T, Liu J, Xie Y, Yuan S, Guo Y, Bai W, Zhao K, Jiang W, Wang H, Wang H, Zhao T, Huang C, Gao S, Wang X, Yang S, Hao J.
Zhou T, et al. Among authors: hao j.
Gut. 2022 Feb;71(2):357-371. doi: 10.1136/gutjnl-2020-321952. Epub 2021 Mar 5.
Gut. 2022.
PMID: 33674341
Free PMC article.